The nanotech versus the biotech revolution: Sources of productivity in incumbent firm research

Research Policy

Volumn 36, Issue 6, 2007, Pages 832-849

  Rothaermel, Frank T ^a   Thursby, Marie ^b  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Alliances and acquisitions; Capability development; R D investments; Research productivity; Tacit knowledge

Indexed keywords

BIOTECHNOLOGY; DRUG PRODUCTS PLANTS; INVESTMENTS; PRODUCTION CONTROL; PRODUCTIVITY; RESEARCH AND DEVELOPMENT MANAGEMENT;

CAPABILITY DEVELOPMENT; RESEARCH PRODUCTIVITY; TACIT KNOWLEDGE;

NANOTECHNOLOGY;

EID: 34250206621     PISSN: 00487333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respol.2007.02.008     Document Type: Article

References (59)

1. Acs Z., and Audretsch D. Patents as a measure of innovative activity. Kyklos 42 (1989) 171-180
2. Adams J.D. Fundamental stock of knowledge and productivity growth. Journal of Political Economy 98 (1990) 678-702
3. Audretsch D.B., and Stephan P.E. Company-scientist locational links: the case of biotechnology. American Economic Review 86 (1996) 641-652
4. Bozeman B., and Mangematin V. Editor's introduction: scientific and technical human capital. Research Policy 33 (2004) 565-568
5. Bozeman B., and Corley E. Scientists' collaboration strategies: implications for scientific and technical human capital. Research Policy 33 (2004) 599-616
6. Cameron A., and Trivedi P. Econometric models based on count data: comparisons and applications of some estimators and tests. Journal of Applied Econometrics 1 (1986) 29-53
7. Catherine D., Corolleur C., Carrere M., and Mangematin V. Turning scientific and technological human capital into economic capital: the experience of biotech start-ups in France. Research Policy 33 (2004) 631-642
8. Cohen S.N., Chang A.C.Y., Boyer H.W., and Helling R. Construction of biologically functional bacterial plasmids in vitro. Proceedings of the National Academy of Sciences USA 70 (1973) 3240-3244
9. Cohen P., Cohen J., West S.G., and Aiken L.S. Applied Multiple Regression/Correlation Analysis for the Behavioral Sciences. third ed. (2003), Erlbaum, Hillsdale, NJ
10. Cohen W.M., and Levinthal D.A. Innovation and learning: the two faces of R&D. Economic Journal 99 (1989) 569-596
11. Evenson R.E., and Kislev Y. Agricultural Research and Productivity (1975), Yale University Press, New Haven, CT
12. Darby, M.R., Zucker, L.G. Grilichesian breakthroughs: inventions of methods of inventing and firm entry in nanotechnology. Annales d'Economie et Statistique, in press.
13. Galambos L., and Sturchio J. Pharmaceutical firms and the transition to biotechnology: a study in strategic innovation. Business History Review 72 Summer (1998) 250-278
14. Gans J.S., and Stern S. Incumbency and R&D incentives: licensing the gale of creative destruction. Journal of Economics and Management Strategy 9 (2000) 485-511
15. Gans J.S., Hsu D.H., and Stern S. When does start-up innovation spur the gale of creative destruction?. RAND Journal of Economics 33 (2002) 571-586
16. Gourieroux C., Montfort A., and Trognon A. Pseudo maximum likelihood methods: applications to Poisson models. Econometrica 52 (1984) 701-720
17. Griliches Z. Hybrid corn: an exploration in the economics of technological change. Econometrica 25 (1957) 501-522
18. Griliches Z. Issues in assessing the contribution of research and development to productivity growth. Bell Journal of Economics 10 (1979) 92-116
19. In: Griliches Z. (Ed). R&D, Patents, and Productivity (1984), Chicago University Press, Chicago, IL
20. Hagedoorn J. Inter-firm R&D partnerships: an overview of major trends and patterns since 1960. Research Policy 31 (2002) 477-482
21. Hagedoorn J., and Cloodt M. Measuring innovative performance: is there an advantage in using multiple indicators?. Research Policy 32 (2003) 1365-1379
22. Hall J., Griliches J., and Hausman J.A. Patents and R&D: Is there a lag?. International Economic Review 27 (1986) 265-284
23. Hall, B.H., Jaffe, A.B., Trajtenberg, M., 2001. The NBER patent citations data file: lessons, insights and methodological tools. NBER Working Paper 8498. Cambridge, MA.
24. Hausman J., Hall B., and Griliches Z. Econometric models for count data with an application to the patents-R&D relationship. Econometrica 52 (1984) 909-938
25. Henderson R.M., and Clark K. Architectural innovation: the reconfiguration of existing product technologies and the failure of established firms. Administrative Science Quarterly 35 (1990) 9-30
26. Henderson R.M., Orsenigo L., and Pisano G.P. The pharmaceutical industry and the revolution in molecular biology: Interactions among scientific, institutional, and organizational change. In: Mowery D.C., and Nelson R.R. (Eds). The Sources of Industrial Leadership (1999), Cambridge University Press, Cambridge, UK 267-311
27. Henderson R.M., and Cockburn I.M. Scale, scope, and spillovers: the determinants of productivity in drug discovery. RAND Journal of Economics 27 (1996) 32-59
28. Higgins M., and Rodriguez D. The outsourcing of R&D through acquisition in the pharmaceutical industry. Journal of Financial Economics 80 (2006) 351-383
29. Hill C.W.L., and Rothaermel F.T. The performance of incumbent firms in the face of radical technological innovation. Academy of Management Review 28 (2003) 257-274
30. Hoang H., and Rothaermel F.T. The effect of general and partner-specific alliance experience on joint R&D project performance. Academy of Management Journal 48 (2005) 332-345
31. Holmstrom B. Agency costs and innovation. Journal of Economic Behavior and Organization 12 (1989) 305-327
32. Hsiao C. Analysis of Panel Data. second ed. (2003), Cambridge University Press, Cambridge, UK
33. Ichino A., and Maggi G. Work environment and individual background: explaining regional shirking differentials in a large Italian firm. Quarterly Journal of Economics 115 (2000) 1057-1090
34. IMS Health, 2003. Global Pharmaceutical Sales by Region, 2002. March 12, 2003.
35. Huang Z., Chen H., Yip A., Ng G., Guo F., Chen Z.K., and Roco M.C. Longitudinal patent analysis for nanoscale science and engineering: country, institution and technology field. Journal of Nanoparticle Research 5 (2003) 333-363
36. Jacobson R. Unobservable effects and business performance. Marketing Science 9 (1990) 74-85
37. Jacoby M. New tools for tiny jobs. Chemical and Engineering News 78 (2000) 33-35
38. Lacetera N., Cockburn I., and Henderson R.M. Do firms change capabilities by hiring new people? A study of the adoption of science-based drug discovery. In: Baum J.A.C., and McGahan A.M. (Eds). Business Strategy over the Industry Lifecycle: Advances in Strategic Management vol. 21 (2004) 133-159
39. Lemley M. Patenting nanotechnology. Stanford Law Review 58 (2005) 601-630
40. Long J.S. Regression Models for Categorical and Limited Dependent Variables (1997), Sage Publications, Thousand Oaks, CA
41. National Academy Press, 1997. Intellectual Property Rights and Research Tools in Molecular Biology. Summary of a Workshop held at the National Academy of Sciences, February 15-16, 1996. Chapter 5, Case Studies: 40-56. National Research Council, Washington, DC.
42. Powell W.W., White D.R., Koput K.W., and Owen-Smith J. Network dynamics and field evolution: the growth of interorganizational collaboration in the life Sciences. American Journal of Sociology 110 (2005) 1132-1205
43. In: Roco M.C., and Bainbridge W.S. (Eds). Societal Implications of Nanoscience and Nanotechnology (2001), Kluwer Academic Publishers, Boston, MA
44. Reinganum J.F. On the timing of innovation. In: Schmalensee R., and Willig R.D. (Eds). Handbook of Industrial Organization. ninth ed. vol. 1 (1989), Amsterdam, North Holland 849-908
45. Rothaermel F.T. Technological discontinuities and the nature of competition. Technology Analysis & Strategic Management 12 (2000) 149-160
46. Rothaermel F.T. Complementary assets, strategic alliances, and the incumbent's advantage: an empirical study of industry and firm effects in the biopharmaceutical industry. Research Policy 30 (2001) 1235-1251
47. Rothaermel, F.T., Hess, A.M. Building dynamic capabilities: innovation driven by individual, firm, and network-level effects. Organization Science 18, in press.
48. Rothaermel F.T., and Hill C.W.L. Technological discontinuities and complementary assets: a longitudinal study of industry and firm performance. Organization Science 16 (2005) 52-70
49. Rothaermel F.T., and Thursby M. University-incubator firm knowledge flows: assessing their impact on incubator firm performance. Research Policy 34 (2005) 305-320
50. Rothaermel F.T., and Thursby M. Incubator firm failure or graduation? The role of university linkages. Research Policy 34 (2005) 1076-1090
51. Sampat, B.N., 2005. Examining patent examination: an analysis of examiner and applicant generated prior art. Working Paper, Columbia University.
52. Schumpeter J. Capitalism, Socialism and Democracy (1942), Harper and Row, New York, NY
53. Stuart T.E. Interorganizational alliances and the performance of firms: a study of growth and innovation rates in a high-technology industry. Strategic Management Journal 27 (2000) 791-811
54. Stuart T.E., Hoang H., and Hybels R.C. Interorganizational endorsements and the performance of entrepreneurial ventures. Administrative Science Quarterly 44 (1999) 315-349
55. Thomas III L.G. The Japanese pharmaceutical industry. Review of Industrial Organization 22 (2003) 889-938
56. Thursby J., Jensen R., and Thursby M. Objectives, characteristics, and outcomes of university licensing: a survey of major U.S. universities. Journal of Technology Transfer 26 (2001) 59-72
57. Vogelsang T.J. Wald-type tests for detecting breaks in the trend function of a dynamic time series. Econometric Theory 13 (1997) 818-849
58. Zucker L., and Darby M. Present at the revolution: transformation of technical identity for a large incumbent pharmaceutical firm after the biotechnological breakthrough. Research Policy 26 (1997) 429-446
59. Zucker L., Darby M., and Brewer M. Intellectual human capital and the birth of U.S. biotechnology enterprises. American Economic Review 88 (1998) 290-306